Literature DB >> 32946651

Stillbirth and fetal anomalies: secondary analysis of a case-control study.

S L Son1,2, A A Allshouse1, J M Page1,2, M P Debbink1,2, H Pinar3, U Reddy4, K J Gibbins1, B J Stoll5, C B Parker6, D J Dudley7, M W Varner1,2, R M Silver1,2.   

Abstract

OBJECTIVE: Approximately 10% of stillbirths are attributed to fetal anomalies, but anomalies are also common in live births. We aimed to assess the relationship between anomalies, by system and stillbirth.
DESIGN: Secondary analysis of a prospective, case-control study.
SETTING: Multicentre, 59 hospitals in five regional catchment areas in the USA. POPULATION OR SAMPLE: All stillbirths and representative live birth controls.
METHODS: Standardised postmortem examinations performed in stillbirths, medical record abstraction for stillbirths and live births. MAIN OUTCOME MEASURES: Incidence of major anomalies, by type, compared between stillbirths and live births with univariable and multivariable analyses using weighted analysis to account for study design and differential consent.
RESULTS: Of 465 singleton stillbirths included, 23.4% had one or more major anomalies compared with 4.3% of 1871 live births. Having an anomaly increased the odds of stillbirth; an increasing number of anomalies was more highly associated with stillbirth. Regardless of organ system affected, the presence of an anomaly increased the odds of stillbirth. These relationships remained significant if stillbirths with known genetic abnormalities were excluded. After multivariable analyses, the adjusted odds ratio (aOR) of stillbirth for any anomaly was 4.33 (95% CI 2.80-6.70) and the systems most strongly associated with stillbirth were cystic hygroma (aOR 29.97, 95% CI 5.85-153.57), and thoracic (aOR16.18, 95% CI 4.30-60.94) and craniofacial (aOR 35.25, 95% CI 9.22-134.68) systems.
CONCLUSIONS: In pregnancies affected by anomalies, the odds of stillbirth are higher with increasing numbers of anomalies. Anomalies of nearly any organ system increased the odds of stillbirth even when adjusting for gestational age and maternal race. TWEETABLE ABSTRACT: Stillbirth risk increases with anomalies of nearly any organ system and with number of anomalies seen.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  Anomaly; congenital anomaly; fetal anomaly; stillbirth

Mesh:

Year:  2020        PMID: 32946651      PMCID: PMC7902300          DOI: 10.1111/1471-0528.16517

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  13 in total

1.  Causes of death among stillbirths.

Authors: 
Journal:  JAMA       Date:  2011-12-14       Impact factor: 56.272

2.  Evaluation of 1025 fetal deaths: proposed diagnostic workup.

Authors:  Fleurisca J Korteweg; Jan Jaap H M Erwich; Albertus Timmer; Jan van der Meer; Joke M Ravisé; Nic J G M Veeger; Jozien P Holm
Journal:  Am J Obstet Gynecol       Date:  2011-10-20       Impact factor: 8.661

3.  Stillbirth Collaborative Research Network: design, methods and recruitment experience.

Authors:  Corette B Parker; Carol J R Hogue; Matthew A Koch; Marian Willinger; Uma M Reddy; Vanessa R Thorsten; Donald J Dudley; Robert M Silver; Donald Coustan; George R Saade; Deborah Conway; Michael W Varner; Barbara Stoll; Halit Pinar; Radek Bukowski; Marshall Carpenter; Robert Goldenberg
Journal:  Paediatr Perinat Epidemiol       Date:  2011-07-28       Impact factor: 3.980

4.  Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.

Authors:  J C Carey; M A Klebanoff; J C Hauth; S L Hillier; E A Thom; J M Ernest; R P Heine; R P Nugent; M L Fischer; K J Leveno; R Wapner; M Varner
Journal:  N Engl J Med       Date:  2000-02-24       Impact factor: 91.245

5.  Infant Mortality in the United States, 2017: Data From the Period Linked Birth/Infant Death File.

Authors:  Danielle M Ely; Anne K Driscoll
Journal:  Natl Vital Stat Rep       Date:  2019-08

6.  Karyotype versus microarray testing for genetic abnormalities after stillbirth.

Authors:  Uma M Reddy; Grier P Page; George R Saade; Robert M Silver; Vanessa R Thorsten; Corette B Parker; Halit Pinar; Marian Willinger; Barbara J Stoll; Josefine Heim-Hall; Michael W Varner; Robert L Goldenberg; Radek Bukowski; Ronald J Wapner; Carolyn D Drews-Botsch; Barbara M O'Brien; Donald J Dudley; Brynn Levy
Journal:  N Engl J Med       Date:  2012-12-06       Impact factor: 91.245

7.  Update on overall prevalence of major birth defects--Atlanta, Georgia, 1978-2005.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2008-01-11       Impact factor: 17.586

8.  Stillbirth and neonatal mortality in pregnancies complicated by major congenital anomalies: Findings from a large European cohort.

Authors:  Henk Groen; Katelijne Bouman; Anna Pierini; Judith Rankin; Anke Rissmann; Martin Haeusler; Lyubov Yevtushok; Maria Loane; Jan Jaap H M Erwich; Hermien E K de Walle
Journal:  Prenat Diagn       Date:  2017-10-06       Impact factor: 3.050

9.  National, regional, and worldwide estimates of stillbirth rates in 2015, with trends from 2000: a systematic analysis.

Authors:  Hannah Blencowe; Simon Cousens; Fiorella Bianchi Jassir; Lale Say; Doris Chou; Colin Mathers; Dan Hogan; Suhail Shiekh; Zeshan U Qureshi; Danzhen You; Joy E Lawn
Journal:  Lancet Glob Health       Date:  2016-01-19       Impact factor: 26.763

10.  National population-based estimates for major birth defects, 2010-2014.

Authors:  Cara T Mai; Jennifer L Isenburg; Mark A Canfield; Robert E Meyer; Adolfo Correa; Clinton J Alverson; Philip J Lupo; Tiffany Riehle-Colarusso; Sook Ja Cho; Deepa Aggarwal; Russell S Kirby
Journal:  Birth Defects Res       Date:  2019-10-03       Impact factor: 2.661

View more
  1 in total

1.  Predicting singleton antepartum stillbirth by the demographic Fetal Medicine Foundation Risk Calculator-A retrospective case-control study.

Authors:  Dana A Muin; Karin Windsperger; Nadia Attia; Herbert Kiss
Journal:  PLoS One       Date:  2022-01-20       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.